Gender, ethnicity and genetics in cardiovascular disease. Part 1: Basic principles

Heart Disease

Volumn 5, Issue 2, 2003, Pages 129-143

  Schaefer, Benjamin M ^a   Caracciolo, Vincent ^b   Frishman, William H ^c   Charney, Pamela ^d,e  

^a JACOBI MEDICAL CENTER   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

^d NORWALK HOSPITAL   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Ethnicity; Gender; Genetics; Pharmacogenetics

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADDUCIN; ADRENERGIC RECEPTOR; ALDOSTERONE SYNTHASE; ANGIOTENSIN 1 RECEPTOR; APOLIPOPROTEIN A; APOLIPOPROTEIN E; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BRADYKININ B2 RECEPTOR; CAPTOPRIL; CLOZAPINE; CYTOCHROME P450; DEBRISOQUINE; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; ESTROGEN; HAPTOGLOBIN; KALLIKREIN; LISINOPRIL; MEPHENYTOIN; NITRIC OXIDE SYNTHASE; PROSTACYCLIN SYNTHASE; QUINIDINE; SALBUTAMOL; SODIUM CHLORIDE; SPARTEINE; UNINDEXED DRUG; WARFARIN; ZILEUTON;

ADRENERGIC SYSTEM; ALCOHOL METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACETYLATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG METABOLISM; ETHNIC DIFFERENCE; FEMALE; FOOD AND DRUG ADMINISTRATION; GENE FREQUENCY; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HORMONE ACTION; HUMAN; HYPERTENSION; MALE; MENSTRUAL CYCLE; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PHARMACOGENETICS; PLASMA PROTEIN BINDING; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SENSITIVITY AND SENSIBILITY; SEX DIFFERENCE; SODIUM RETENTION;

CARDIOVASCULAR DISEASES; CONTINENTAL POPULATION GROUPS; HUMANS; POLYMORPHISM, GENETIC; SEX FACTORS; UNITED STATES;

EID: 0038752690     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hdx.0000061694.62343.01     Document Type: Review

References (250)

1. Charney P, Morgan C. Do treatment recommendations reported in the research literature consider differences between women and men? J Womens Health. 1996;5:579-584.
2. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2000;343:475-80.
3. Wieringa NF, de Graeff PA, van der Werf GT, et al. Cardiovascular drugs: discrepancies in demographics between pre- and post-registration use. Eur J Clin Pharmacol. 1999;55:537-44.
4. Skett P. Biochemical basis of sex differences in drug metabolism. Pharmacol Ther. 1988;38:269-304.
5. Evans DA, McLeod HL, Pritchard S, et al. Interethnic variability in human drug responses. Drug Metab Dispos. 2001;29:606-10.
6. Giudicelli JF, Tillement JP. Influence of sex on drug kinetics in man. Clin Pharmacokinet. 1977;2:157-66.
7. Wentz AC. Women's health issues. Adv Intern Med. 1995;40:1-30.
8. Merkatz RB, Temple R, Subel S, et al. Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials. N Engl J Med. 1993;329:292-6.
9. Luft FC. Molecular genetics of human hypertension. Curr Opin Nephrol Hypertens. 2000;9:259-66.
10. Levine WG, Frishman WH. Basic principles of clinical pharmacology relevant to cardiology. In: Frishman WH, Sonnenblick EH, Sica D, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York, NY: McGraw-Hill; 2003;313
11. Kim JS, Nafziger AN. Is it sex or is it gender? Clin Pharmacol Ther. 2000;68:1-3.
12. Anthropologists AAOP. American Anthropological Association Statement on "Race". AJPA. 1996;101:569-570.
13. Schwartz RS. Racial profiling in medical research. N Engl J Med. 2001;344:1392-93.
14. Schmitt, E. For 7 million people in census, one race category isn't enough. New York Times. March 13, 2001; Section A:1.
15. Bhopal R. Is research into ethnicity and health racist, unsound, or important science? Br Med J. 1997;314:1751-56.
16. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicine: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94:1-26.
17. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicine: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94:1-26.
18. Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat. 1998;11:1-3.
19. Staessen JA, Ginocchio G, Wang JG, et al. Genetic variability in the renin-angiotensin system: prevalence of alleles and genotypes. J Cardiovasc Risk. 1997;4:401-22.
20. Sagnella GA, Rothwell MJ, Onipinla AK, et al. A population study of ethnic variations in the angiotensin-converting enzyme I/D polymorphism: relationships with gender, hypertension and impaired glucose metabolism. J Hypertens. 1999;17:657-64.
21. Fornage M, Amos CI, Kardia S, et al. Variation in the region of the angiotensin-converting enzyme gene influences interindividual differences in blood pressure levels in young white males. Circulation. 1998;97:1773-79.
22. Cheung BM, Kumana CR. Association studies of genetic polymorphisms and complex disease. Lancet. 2000;355:1277.
23. Levy SB, Lilley JJ, Frigon RP, et al. Urinary kallikrein and plasma renin activity as determinants of renal blood flow. The influence of race and dietary sodium intake. J Clin Invest. 1977;60:129-38.
24. Zinner SH, Margolius HS, Rosner B, et al. Stability of blood pressure rank and urinary kallikrein concentration in childhood: an eight-year follow-up. Circulation. 1978;58:908-15.
25. Gainer JV, Stein CM, Neal T, et al. Interactive effect of ethnicity and ACE insertion/deletion polymorphism on vascular reactivity. Hypertension. 2001;37:46-51.
26. Nakagawa K, Ishizaki T. Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. Pharmacol Ther. 2000;86:1-28.
27. Barley J, Carter ND, Cruickshank JK, et al. Renin and atrial natriuretic peptide restriction fragment length polymorphisms: association with ethnicity and blood pressure. J Hypertens. 1991;9:993-96.
28. Wolbrette D, Patel H. Arrhythmias and women. Curr Opin Cardiol. 1999;14:36-43.
29. Lang CC, Stein CM, Brown RM, et al. Attenuation of isoproterenolmediated vasodilatation in blacks. N Engl J Med. 1995;333:155-60.
30. Bengtsson K, Orho-Melander M, Melander O, et al. Beta(2)-adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes. Hypertension. 2001;37:1303-08.
31. Brodde OE, Buscher R, Tellkamp R, et al. Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors. Circulation. 2001;103:1048-50.
32. Feldman RD. Adrenergic receptor polymorphisms and cardiac function (and dysfunction): a failure to communicate? Circulation. 2001;103:1042-43.
33. Hindorff LA, Schwartz SM, Siscovick DS, et al. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk. 2002; 9:131-37.
34. Sakata T, Kario K, Katayama Y, et al. Studies on congenital protein C deficiency in Japanese: prevalence, genetic analysis, and relevance to the onset of arterial occlusive diseases. Semin Thromb Hemost. 2000; 26:11-16.
35. Franco RF, Pazin-Filho A, Tavella MH, et al. Factor XIII va134leu and the risk of myocardial infarction. Haematologica. 2000;85:67-71.
36. Girelli D, Russo C, Ferraresi P, et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med. 2000;343:774-80.
37. Psaty BM, Smith NL, Lemaitre RN, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA. 2001;285:906-13.
38. Humphries SE, Luong LA, Ogg MS, et al. The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2001;22:2243-52.
39. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185-92.
40. Iwai N, Katsuya T, Ishikawa K, et al. Human prostacyclin synthase gene and hypertension: the Suita Study. Circulation. 1999;100:2231-36.
41. De Bacquer D, De Backer G, Langlois M, et al. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis. 2001;157:161-66.
42. Matsubara M, Kikuya M, Ohkubo T, et al. Aldosterone synthase gene (CYP11B2) C-334T polymorphism, ambulatory blood pressure and nocturnal decline in blood pressure in the general Japanese population: the Ohasama Study. J Hypertens. 2001;19:2179-84.
43. Cai H, Duarte N, Wilcken DE, Wang XL. NADH/NADPH oxidase p22 phox C242T polymorphism and coronary artery disease in the Australian population. Eur J Clin Invest. 1999;29:744-48.
44. Guzik TJ, West NE, Black E, et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation. 2000;102:1744-47.
45. Jakubowski H, Ambrosius WT, Pratt JH. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett. 2001;491:35-39.
46. Imai Y, Morita H, Kurihara H, et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis. 2000;149:435-42.
47. Voetsch B, Benke KS, Damasceno BP, et al. Paraoxonase 192 Gln>Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke. 2002;33:1459-64.
48. Morita H, Kurihara H, Sugiyama T, et al. Polymorphism of the methionine synthase gene: association with homocysteine metabolism and late-onset vascular diseases in the Japanese population. Arterioscler Thromb Vasc Biol. 1999;19:298-302.
49. McGladdery SH, Pimstone SN, Clee SM, et al. Common mutations in the lipoprotein lipase gene (LPL): effects on HDL-cholesterol levels in a Chinese Canadian population. Atherosclerosis. 2001;156:401-07.
50. Chen W, Srinivasan SR, Elkasabany A, et al. Influence of lipoprotein lipase serine 447 stop polymorphism on tracking of triglycerides and HDL cholesterol from childhood to adulthood and familial risk of coronary artery disease: the Bogalusa heart study. Atherosclerosis. 2001;159:367-73.
51. Hall S, Talmud PJ, Cook DG, et al. Frequency and allelic association of common variants in the lipoprotein lipase gene in different ethnic groups: the Wandsworth Heart and Stroke Study. Genet Epidemiol. 2000;18:p. 203-16.
52. Dilley A, Hooper WC, El-Jamil M, Renshaw M, Wenger NK, Evatt BL. Mutations in the genes regulating methylene tetrahydrofolate reductase (MTHFR C->T677) and cystathione beta-synthase (CBS G->A919, CBS T->c833) are not associated with myocardial infarction in African-Americans. Thromb Res. 2001;103:109-15.
53. Hsu LA, Ko YL, Wang SM, et al. The C677T mutation of the methyl-enetetrahydrofolate reductase gene is not associated with the risk of coronary artery disease or venous thrombosis among Chinese in Taiwan. Hum Hered. 2001;51:41-45.
54. Splawski I, Shen J, Timothy LW, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 2000;102:1178-85.
55. Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. Circulation. 1999;99:674-81.
56. Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation. 1999;99:518-28.
57. Grim CE, Robinson M. Blood pressure variation in blacks: genetic factors. Semin Nephrol. 1996;16:83-93.
58. Dong Y, Zhu H, Sagnella GA, et al. Association between the C825T polymorphism of the G protein beta3-subunit gene and hypertension in blacks. Hypertension. 1999;34:1193-96.
59. Su YR, Menon AG. Epithelial sodium channels and hypertension. Drug Metab Dispos. 2001;29:553-56.
60. Luft FC. Monogenic hypertension: lessons from the genome. Kidney Int. 2001;60:381-90.
61. Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289:119-23.
62. Lovati E, Ferrari P, Dick B, et al. Molecular basis of human salt sensitivity: the role of the 11 beta-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab. 1999;84:3745-49.
63. Svetkey LP, Timmons PZ, Emovon O, et al. Association of hypertension with beta2- and alpha2c10-adrenergic receptor genotype. Hypertension. 1996;27:1210-15.
64. Svetkey LP, Chen YT, McKeown SP, et al. Preliminary evidence of linkage of salt sensitivity in black Americans at the beta 2-adrenergic receptor locus. Hypertension. 1997;29:918-22.
65. Weir MR, Chrysant SG, McCarron DA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension. 1998;31:1088-96.
66. Chrysant SG, Weir MR, Weder AB, et al. There are no racial, age, sex, or weight differences in the effect of salt on blood pressure in saltsensitive hypertensive patients. Arch Intern Med. 1997;157:2489-94.
67. Wilson DK, Bayer L, Sica DA. Variability in salt sensitivity classifications in black male versus female adolescents. Hypertension. 1996; 28:250-55.
68. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-11.
69. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med. 2002;346:340-52.
70. Kadish AH, Frishman WH, Daugherty S, et al. Effect of hormone replacement on myocardial repolarization: a Women's Health Initiative substudy (abstr). Circulation. 2002;106(Suppl II):II-460.
71. Kashuba AD, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet. 1998;34:203-18.
72. Kawano H, Motoyama T, Ohgushi M, et al. Menstrual cyclic variation of myocardial ischemia in premenopausal women with variant angina. Ann Intern Med. 2001;135:977-81.
73. Charney P. Coronary artery disease in young women: the menstrual cycle and other risk factors. Ann Intern Med. 2001;135:1002-04.
74. Freedman RR, Girgis R. Effects of menstrual cycle and race on peripheral vascular alpha-adrenergic responsiveness. Hypertension. 2000;35:795-99.
75. Mills PJ, Ziegler MG, Nelesen RA, Kennedy BP. The effects of the menstrual cycle, race, and gender on adrenergic receptors and agonists. Clin Pharmacol Ther. 1996;60:99-104.
76. Ahwal WN, Mills PJ, Kalshan DA, Nelesen RA. Effects of race and sex on blood pressure and hemodynamic stress response as a function of the menstrual cycle. Blood Press Monit. 1997;2:161-67.
77. Mills PJ, Nelesen RA, Ziegler MG, et al. Menstrual cycle effects on catecholamine and cardiovascular responses to acute stress in black but not white normotensive women. Hypertension. 1996;27:962-67.
78. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-13.
79. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6. 8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57.
80. Anonymous. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33.
81. Evans RR, Phillips BG, Singh G, et al. Racial and gender differences in endothelin-1. Am J Cardiol. 1996;78:486-88.
82. Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. 1996;28:652-55.
83. Treiber FA, Jackson RW, Davis H, et al. Racial differences in endothelin-1 at rest and in response to acute stress in adolescent males. Hypertension. 2000;35:722-25.
84. Ergul S, Ergul A, Hudson JA, et al. The effect of regulation of high blood pressure on plasma endothelin-1 levels in blacks with hypertension. Am J Hypertens. 1998;11:1381-85.
85. Ergul A, Shoemaker K, Puett D, Tackett RL. Gender differences in the expression of endothelin receptors in human saphenous veins in vitro. J Pharmacol Exp Ther. 1998;285:511-17.
86. Ergul A, Tackett RL, Puett D. Distribution of endothelin receptors in saphenous veins of African-Americans: implications of racial differences. J Cardiovasc Pharmacol. 1999;34:327-32.
87. Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med. 1998;338:784-90.
88. Frishman WH, Kaur S, Singh I, Tamirisa P: Endothelin as a therapeutic target in the treatment of cardiovascular disease. In: Frishman WH, Sonnenblick EH, Sica D, eds. Cardiovascular Pharmacotherapeutics 2nd ed. New York, NY: McGraw-Hill; 2003:52743.
89. Mallamaci F, Cuzzola F, Tripepi G, et al. Gender-dependent differences in plasma leptin in essential hypertension. Am J Hypertens. 2000;13:914-20.
90. Uckaya G, Ozata M, Sonmez A, et al. Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension. Horm Metab Res. 1999;31:435-38.
91. Sheu WH, Lee WJ, Chen YT. High plasma leptin concentrations in hypertensive men but not in hypertensive women. J Hypertens. 1999; 17:1289-95.
92. Paolisso G, Tagliamonte MR, Galderisi M, et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulinresistant men. Hypertension. 1999;34:1047-52.
93. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab. 1999;84:3686-95.
94. Ergul A. Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension. Hypertension. 2000; 36:62-67.
95. Stein CM, Lang CC, Xie HG, Wood AJ. Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race. Pharmacogenetics. 2001;11:95-110.
96. Johnson JA, Burlew BS, Stiles RN. Racial differences in beta-adrenoceptor-mediated responsiveness. J Cardiovasc Pharmacol. 1995;25:90-96.
97. May DG. Genetic differences in drug disposition. J Clin Pharmacol. 1994;34:881-97.
98. Cheng JWM. Cytochrome P450-mediated cardiovascular drug interactions. Heart Disease. 2000;2:254-58.
99. Fromm MF, Kroemer HK, Eichelbaum M. Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs. Adv Drug Deliv Rev. 1997;27:171-199.
100. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:41-57.
101. Ball SE, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther. 1999;66:288-94.
102. Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African-American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther. 2000;68:82-91.
103. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther. 1990;46:377-94.
104. Agundez JA, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther. 1995;57:265-69.
105. McLellan RA, Oscarson M, Seidegard K, et al. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics. 1997; 7:187-91.
106. Griese EU, Ilett LF, Kitteringham NR, et al. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia. Pharmacogenetics. 2001;11:69-76.
107. Lin Y, Anderson GD, Kantor E, et al. Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women. J Clin Pharmacol. 1999;39:578-82.
108. Chida M, Yokoi T, Kosaka Y, et al. Genetic polymorphism of CYP2D6 in the Japanese population. Pharmacogenetics. 1999;9:601-05.
109. Gaedigk A. Interethnic differences of drug-metabolizing enzymes. Int J Clin Pharmacol Ther. 2000;38:61-68.
110. Lennard MS, Iyun AO, Jackson PR, et al. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogeneties. 1992;2:89-92.
111. Simooya OO, Njunju E, Hodjegan AR, et al. Debrisoquine and metoprolol oxidation in Zambians: a population study. Pharmacogenetics. 1993;3:205-08.
112. Griese EU, Asante-Poku S, Ofori-Adjei D, et al. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics. 1999;9:715-23.
113. Bathum L, Skjelbo E, Mutabingwa TK, et al. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol. 1999;48:395-401.
114. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414-23.
115. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717-19.
116. Xie HG, Xu ZH, Luo X, et al. Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: a meta-analysis. Pharmacogenetics. 1996;6:235-38.
117. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999;24:339-46.
118. Kashuba AD, Nafziger AN, Kearns GL, et al. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics. 1998;8:403-10.
119. Tsunoda SM, Harris RZ, Mroczkowski PJ, Benet LZ. Preliminary evaluation of progestins as inducers of cytochrome P450 3A4 activity in postmenopausal women. J Clin Pharmacol. 1998;38:1137-43.
120. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Ann Rev Pharmacol Toxicol. 2001;41:815-50.
121. Min DI, Lee M, Ku YM, Flanigan M. Gender-dependent racial difference in disposition of cyclosporine among healthy African-American and white volunteers. Clin Pharmacol Ther. 2000;68:478-86.
122. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104:147-53.
123. Westphal K, Weinbrenner A, Giessmann T, et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther. 2000;68:6-12.
124. Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther. 1999;66:338-45.
125. Durr D, Stieger B, Kullak-Ublick GA, et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000;68:598-604.
126. Pauli-Magnus C, von Richter O, Burk O, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of Pglycoprotein. J Pharmacol Exp Ther. 2000;293:376-82.
127. Schaeffeler E, Eichelbaum M, Brinkmann U, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 2001;358:383-84.
128. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African-Americans. Clin Pharmacol Ther. 2001;70:189-99.
129. Korrapati MR, Sorkin JD, Andres R, et al. Acetylator phenotype in relation to age and gender in the Baltimore Longitudinal Study of Aging. J Clin Pharmacol. 1997;37:83-91.
130. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther. 1992;52:643-58.
131. Bell DA, Taylor JA, Butler MA, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis. 1993;14:1689-92.
132. Delomenie C, Sica L, Grant DM, et al. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics. 1996;6:177-85.
133. Wood AJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet. 1991;20:350-73.
134. Koup JR, Abel RB, Smithers JA, et al. Effect of age, gender, and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets. Ther Drug Monit. 1998;20:73-77.
135. German JB, Walzem RL. The health benefits of wine. Annu Rev Nutr. 2000;20:561-93.
136. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med. 1993;329:1829-34.
137. Frezza M, di Padova C, Pozzato G, et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med. 1990;322:95-99.
138. Mumenthaler MS, Taylor JL, O'Hara R, et al. Effects of menstrual cycle and female sex steroids on ethanol pharmacokinetics. Alcohol Clin Exp Res. 1999;23:250-55.
139. Oneta CM, Simanowski UA, Martinez M, et al. First pass metabolism of ethanol is strikingly influenced by the speed of gastric emptying. Gut. 1998;43:612-19.
140. Ginsburg ES, Mello NK, Mendelson JH, et al. Effects of alcohol ingestion on estrogens in postmenopausal women. JAMA. 1996;276:1747-51.
141. Ferguson RA, Goldberg DM. Genetic markers of alcohol abuse. Clin Chim Acta. 1997;257:199-250.
142. Shen YC, Fan JH, Edenberg HJ, et al. Polymorphism of ADH and ALDH genes among four ethnic groups in China and effects upon the risk for alcoholism. Alcohol Clin Exp Res. 1997;21:1272-77.
143. Wall TL, Garcia-Andrade C, Thomasson HR, et al. Alcohol dehydrogenase polymorphisms in Native Americans: identification of the ADH2*3 allele. Alcohol Alcohol. 1997;32:129-32.
144. Ehlers CL, Gilder DA, Harris L, Carr L. Association of the ADH2*3 allele with a negative family history of alcoholism in African-American young adults. Alcohol Clin Exp Res. 2001;25:1773-77.
145. Wall TL, Peterson CM, Peterson KP, et al. Alcohol metabolism in Asian-American men with genetic polymorphisms of aldehyde dehydrogenase. Ann Intern Med. 1997;127:376-79.
146. Hines LM, Stampfer MJ, Ma J, et al. Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. N Engl J Med. 2001;344:549-55.
147. Teng YS, Jehan S, Lie-Injo LE. Human alcohol dehydrogenase ADH2 and ADH3 polymorphisms in ethnic Chinese and Indians of West Malaysia. Hum Genet. 1979;53:87-90.
148. Klatsky AL, Friedman GD, Siegelaub AB. Alcohol use and cardiovascular disease: the Kaiser-Permanente experience. Circulation. 1981;64:32-41.
149. Maskarinec G, Meng L, Kolonel LN. Alcohol intake, body weight, and mortality in a multiethnic prospective cohort. Epidemiology. 1998;9:654-61.
150. Hanna EZ, Chou SP, Grant BF. The relationship between drinking and heart disease morbidity in the United States: results from the National Health Interview Survey. Alcohol Clin Exp Res. 1997;21:111-18.
151. Miners JO, Attwood J, Birkett DJ. Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol. 1983;16:503-09.
152. Miners JO, Robson RA, Birkett DJ. Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination. Br J Clin Pharmacol. 1984;18:240-43.
153. Bennett BM, Twiddy DA, Moffat JA, et al. Sex-related difference in the metabolism of isosorbide dinitrate following incubation in human blood. Biochem Pharmacol. 1983;32:3729-34.
154. Wald A, Van Thiel DH, Hoechstetter L, et al. Gastrointestinal transit: the effect of the menstrual cycle. Gastroenterology. 1981;80:1497-500.
155. Gill RC, Murphy PD, Hooper HR, et al. Effect of the menstrual cycle on gastric emptying. Digestion. 1987;36:168-74.
156. Lee RV. Symptoms produced by normal physiologic changes in pregnancy. In: Medical Care of the Pregnant Patient. Lee RV et al, eds. Philadelphia, PA: American College of Physicians; 2000;5268
157. Johnson JA. Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci. 1997;86:1328-33.
158. Wilsgaard T, Schirmer H, Arnesen E. Impact of body weight on blood pressure with a focus on sex differences: the Tromso Study, 1986-1995. Arch Intern Med. 2000;160:2847-53.
159. Chen ML, Lee SC, Ng MJ, et al. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther. 2000;68:510-21.
160. Beierle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther. 1999;37:529-47.
161. Xie HG, Kim RB, Stein CM, et al. Alpha1A-adrenergic receptor polymorphism: association with ethnicity but not essential hypertension. Pharmacogenetics. 1999;9:651-56.
162. Snapir A, Heinonen P, Tuomainen TP, et al. An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events. J Am Coll Cardiol. 2001;37:1516-22.
163. Lockette W, Ghosh S, Farrow S, et al. Alpha 2-adrenergic receptor gene polymorphism and hypertension in blacks. Am J Hypertens. 1995;8:390-94.
164. Small KM, Wagoner LE, Levin AM, et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002;347:1135-42.
165. Morrison AC, Bray MS, Folsom AR, Boerwinkle E. ADD1 460W allele associated with cardiovascular disease in hypertensive individuals. Hypertension. 2002;39:1053-57.
166. Balkestein EJ, Staessen JA, Wang JG, et al. Carotid and femoral artery stiffness in relation to three candidate genes in a white population. Hypertension. 2001;38:1190-97.
167. Nakano Y, Oshima T, Watanabe M, et al. Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension. Am J Hypertens. 1997;10:1064-68.
168. Stavroulakis GA, Makris TK, Krespi PG, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther. 2000;14:427-32.
169. Jalil JE, Piddo AM, Cordova S, et al. Prevalence of the angiotensin I converting enzyme insertion/deletion polymorphism, plasma angiotensin converting enzyme activity, and left ventricular mass in a normotensive Chilean population. Am J Hypertens. 1999;12:697-704.
170. Linhart A, Sedlacek K, Jachymova M, et al. Lack of association of angiotensin-converting enzyme and angiotensinogen genes polymorphisms with left ventricular structure in young normotensive men. Blood Press. 2000;9:47-51.
171. Rodriguez-Perez JC, Rodriguez-Esparragon F, Hernandez-Perera O, et al. Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: the PROCAGENE study. J Am Coll Cardiol. 2001;37:1536-42.
172. Matsubara M, Suzuki M, Fujiwara T, et al. Angiotensin-converting enzyme I/D polymorphism and hypertension:the Ohasama study. J Hypertens. 2002;20:1121-26.
173. Fuentes RM, Perola M, Nissinen A, et al. ACE gene and physical activity, blood pressure, and hypertension: a population study in Finland. J Appl Physiol. 2002;92:2508-12.
174. Forrester T, McFarlane-Anderson N, Bennett FI, et al. The angiotensin converting enzyme and blood pressure in Jamaicans. Am J Hypertens. 1997;10:519-24.
175. Eichner JE, Christiansen VJ, Moore WE, et al. Angiotensin-converting enzyme gene polymorphism in a cohort of coronary angiography patients. Atherosclerosis. 2001;154:673-79.
176. Wang XL, McCredie RM, Wilcken DE. Genotype distribution of angiotensin-converting enzyme polymorphism in Australian healthy and coronary populations and relevance to myocardial infarction and coronary artery disease. Arterioscler Thromb Vasc Biol. 1996; 16:115-19.
177. Tsukada K, Ishimitsu T, Tsuchiya N, et al. Angiotensin-converting enzyme gene polymorphism and cardiovascular endocrine system in coronary angiography patients. Jpn Heart J. 1997;38:799-810.
178. Krizanova O, Obdrzalkova D, Polakova H, et al. Molecular variants of the renin-angiotensin system components in the Slovak population. Physiol Res. 1997;46:357-61.
179. Gharavi AG, Lipkowitz MS, Diamond JA, et al. Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension. Am J Cardiol. 1996;77:1315-19.
180. Jian M, Cao X, Huang J, et al. Polymorphism of angiotensin I converting enzyme gene in the older Chinese: linked to ambulatory blood pressure levels and circadian blood pressure rhythm. Int J Cardiol. 1996;55:33-40.
181. Sanderson JE, Young RP, Yu CM, et al. Lack of association between insertion/deletion polymorphism of the angiotensin-converting enzyme gene and end-stage heart failure due to ischemic or idiopathic dilate cardiomyopathy in the Chinese. Am J Cardiol. 1996;77:1008-10.
182. Kario K, Kanai N, Saito K, et al. Ischemic stroke and the gene for angiotensin-converting enzyme in Japanese hypertensives. Circulation. 1996;93:1630-33.
183. Bloem LJ, Manatunga AK, Pratt JH. Racial difference in the
184. Gardemann A, Fink M, Stricker J, et al. ACE I/D gene polymorphism: presence of the ACE D allele increases the risk of coronary artery disease in younger individuals. Atherosclerosis. 1998;139:153-59.
185. Missouris CG, Barley J, Jeffery S, et al. Genetic risk for renal artery stenosis: association with deletion polymorphism in angiotensin 1-converting enzyme gene. Kidney Int. 1996;49:534-37.
186. Nakai K, Itoh C, Miura Y, et al. [Deletion polymorphism of the angiotensin I-converting enzyme gene associates with increased risk for ischemic heart diseases in the Japanese]. Rinsho Byori. 1995;43:347-52.
187. Morris BJ, Zee RY, Schrader AP. Different frequencies of angiotensinconverting enzyme genotypes in older hypertensive individuals. J Clin Invest. 1994;94:1085-89.
188. Ishigami T, Iwamoto T, Tamura K, et al. Angiotensin I converting enzyme (ACE) gene polymorphism and essential hypertension in Japan. Ethnic difference of ACE genotype. Am J Hypertens. 1995;8:95-97.
189. Kauma H, Paivansalo M, Savolainen MJ, et al. Association between angiotensin converting enzyme gene polymorphism and carotid atherosclerosis. J Hypertens. 1996;14:1183-87.
190. Jeng JR. Carotid thickening, cardiac hypertrophy, and angiotensin converting enzyme gene polymorphism in patients with hypertension. Am J Hypertens. 2000;13:111-19.
191. Jeron A, Hengstenberg C, Engel S, et al. The D-allele of the ACE poly-morphism is related to increased QT dispersion in 609 patients after myocardial infarction. Eur Heart J. 2001;22:663-68.
192. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation. 1995;92:1387-88.
193. Ueda S, Elliott HL, Morton JJ, et al. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension. 1995;25:1266-69.
194. Staessen JA, Wang JG, Ginocchio G, et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens. 1997;15:1579-92.
195. Ueda S, Meredith PA, Morton JJ, et al. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation. 1998;98:2148-53.
196. Todd GP, Chadwick IG, Higgins KS, et al. Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. Br J Clin Pharmacol. 1995;39:131-34.
197. Keavney B, McKenzie C, Parish S, et al. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet. 2000;355:434-42.
198. Spiering W, Kroon AA, Fuss-Lejeune MM, et al. Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet. Hypertension. 2000;36:411-16.
199. Nalogowska-Glosnicka K, Lacka BI, Zychma MJ, et al. Angiotensin II type 1 receptor gene A1166C polymorphism is associated with the increased risk of pregnancy-induced hypertension. Med Sci Monit. 2000;6:523-29.
200. Chiu L, Hamman RF, Kamboh MI. Apolipoprotein A polymorphisms and plasma lipoprotein(a) concentrations in non-Hispanic Whites and Hispanics. Hum Biol. 2000;72:821-35.
201. Qin S, Wang S, Li C. Apolipoprotein (a) polymorphism in relation to coronary heart disease in Chinese Han nationality. Zhonghua Yi Xue Za Zhi. 1995;75:588-638.
202. Wang XL, Badenhop R, Humphrey KE, Wilcken DE. New MspI polymorphism at +83 bp of the human apolipoprotein AI gene: association with increased circulating high density lipoprotein cholesterol levels. Genet Epidemiol. 1996;13:1-10.
203. Hanon O, Girerd X, Luong V, et al. Association between the apolipoprotein E polymorphism and arterial wall thickness in asymptomatic adults. J Hypertens. 2000;18:431-36.
204. Eichner JE, Kuller LH, Ferrell RE, et al. Phenotypic effects of apolipoprotein structural variation on lipid profiles. IV. Apolipoprotein polymorphisms in a small group of black women from the healthy women study. Genet Epidemiol. 1989;6:681-89.
205. Xhignesse M, Lussier-Cacan S, Sing CF, et al. Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler Thromb. 1991;11:1100-10.
206. Srinivasan SR, Ehnholm C, Wattigney WA, et al. The relation of apolipoprotein E polymorphism to multiple cardiovascular risk in children: the Bogalusa Heart Study. Atherosclerosis. 1996;123:33-42.
207. Muros M, Rodriguez-Ferrer C. Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp(a) in a Spanish population underexpressing apo E4. Atherosclerosis. 1996;121:13-21.
208. St-Amand J, Prud'homme D, Moorjani S, et al. Apolipoprotein E polymorphism and the relationships of physical fitness to plasma lipoprotein-lipid levels in men and women. Med Sci Sports Exer. 1999;31:692-97.
209. Pablos-Mendez A, Mayeux R, Ngai C, et al. Association of apo E polymorphism with plasma lipid levels in a multiethnic elderly population. Arterioscler Thromb Vasc Biol. 1997;17:3534-41.
210. Guz G, Nurhan Ozdemir F, Sezer S, et al. Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. Am J Kidney Dis. 2000;36:826-36.
211. Srinivasan SR, Ehnholm C, Elkasabany A, et al. Apolipoprotein E polymorphism modulates the association between obesity and dyslipidemias during young adulthood: The Bogalusa Heart Study. Metabolism. 2001;50:696-702.
212. Kao JT, Tsai KS, Chang CJ, et al. The effects of apolipoprotein E polymorphism on the distribution of lipids and lipoproteins in the Chinese population. Atherosclerosis. 1995;114:55-59.
213. Haffner SM, Stern MP, Miettinen H, et al. Apolipoprotein E polymorphism and LDL size in a biethnic population. Arterioscler Thromb Vasc Biol. 1996;16:1184-88.
214. Loktionov A, Vorster H, O'Neill IK, et al. Apolipoprotein E and methylene-tetrahydrofolate reductase genetic polymorphisms in relation to other risk factors for cardiovascular disease in UK Caucasians and Black South Africans. Atherosclerosis. 1999;145:125-35.
215. Sorli JV, Velert R, Guillen M, et al. Effects of the apolipoprotein E poly-morphism on plasma lipid levels and cardiovascular disease risk in a Mediterranean population. Med Clin (Barc). 2002;118:569-74.
216. Ranade K, Jorgenson E, Sheu WH, et al. A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet. 2002;70:935-42.
217. Podlowski S, Wenzel K, Luther HP, et al. Beta1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J Mol Med. 2000;78:87-93.
218. Mason DA, Moore JD, Green SA, et al. A gain-of-function polymorphism in a G-protein coupling domain of the human beta 1-adrenergic receptor. J Biol Chem. 1999;274:12670-74.
219. Ellsworth DL, Coady SA, Chen W, et al. Influence of the beta2-adrenergic receptor Arg16Gly polymorphism on longitudinal changes in obesity from childhood through young adulthood in a biracial cohort: the Bogalusa Heart Study. Int J Obes Relat Metab Disord. 2002;26:928-37.
220. Dishy V, Sofowora GG, Xie HG, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med. 2001;345:1030-35.
221. Cockcroft JR, Gazis AG, Cross DJ, et al. Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension. 2000;36:371-75.
222. Gratze G, Fortin J, Labugger R, et al. Beta-2 Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension. 1999;33:1425-30.
223. Kotanko P, Binder A, Tasker J, et al. Essential hypertension in African Caribbeans associates with a variant of the beta2-adrenoceptor. Hypertension. 1997;30:773-76.
224. Candy G, Samani N, Norton G, et al. Association analysis of beta2 adrenoceptor polymorphisms with hypertension in a Black African population. J Hypertens. 2000;18:167-72.
225. Timmermann B, Mo R, Luft FC, et al. Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. Kidney Int. 1998;53:1455-60.
226. Kato N, Sugiyama T, Morita H, et al. Association analysis of beta(2)-adrenergic receptor polymorphisms with hypertension in Japanese. Hypertension. 2001;37:286-92.
227. Busjahn A, Li GH, Faulhaber HD, et al. Beta-2 adrenergic receptor gene variations, blood pressure, and heart size in normal twins. Hypertension. 2000;35:555-60.
228. Liggett SB, Wagoner LE, Craft LL, et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest. 1998;102:1534-39.
229. Mukae S, Aoki S, Itoh S, et al. Promoter polymorphism of the beta2 bradykinin receptor gene is associated with essential hypertension. Jpn Circ J. 1999;63:759-62.
230. Gainer JV, Brown NJ, Bachvarova M, et al. Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. Am J Hypertens. 2000;13:1268-73.
231. Wang B, Dang A, Liu G. Genetic variation in the promoter region of the beta2 bradykinin receptor gene is associated with essential hypertension in a Chinese Han population. Hypertens Res. 2001;24:299-302.
232. Erdmann J, Hegemann N, Weidemann A, et al. Screening the human bradykinin B2 receptor gene in patients with cardiovascular diseases: identification of a functional mutation in the promoter and a new coding variant (T21M). Am J Med Genet. 1998;80:521-25.
233. Brull D, Dhamrait S, Myerson S, et al. Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. Lancet. 2001;358:1155-56.
234. Stangl K, Cascorbi I, Laule M, et al. High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics. 2000;10:133-40.
235. Chen W, Srinivasan SR, Elkasabany A, et al. Combined effects of endothelial nitric oxide synthase gene polymorphism (G894T) and insulin resistance status on blood pressure and familial risk of hypertension in young adults: the Bogalusa Heart Study. Am J Hypertens. 2001;14:1046-52.
236. Schneider MP, Erdmann J, Delles C, et al. Functional gene testing of the Glu298Asp polymorphism of the endothelial NO synthase. J Hypertens. 2000;18:1767-73.
237. Tsujita Y, Baba S, Yamauchi R, et al. Association analyses between genetic polymorphisms of endothelial nitric oxide synthase gene and hypertension in Japanese: The Suita Study. J Hypertens. 2001;19:1941-48.
238. Hooper WC, Lally C, Austin H, et al. The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African-Americans. Chest. 1999;116:880-86.
239. Alvarez R, Gonzalez P, Batalla A, et al. Association between the NOS3 (-786 T/C) and the ACE (I/D) DNA genotypes and early coronary artery disease. Nitric Oxide. 2001;5:343-48.
240. Yoshimura M, Yasue H, Nakayama M, et al. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet. 1998;103;65-9.
241. Shimasaki Y, Yasue H, Yoshimura M, et al. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol. 1998;31:1506-10.
242. Kim CH, Hwang KY, Choi TM, et al. The methylenetetrahydrofolate reductase gene polymorphism in Koreans with coronary artery disease. Int J Cardiol. 2001;78:13-17.
243. Wrone EM, Zehnder JL, Hornberger JM, et al. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int. 2001;60:1106-13.
244. Gulec S, Aras O, Akar E, et al. Methylenetetrahydrofolate reductase gene polymorphism and risk of premature myocardial infarction. Clin Cardiol. 2001;24:281-84.
245. Johnson JA, Livingston TN. Differences between blacks and whites in plasma protein binding of drugs. Eur J Clin Pharmacol. 1997;51:485-88.
246. Zhou HH, Adedoyin A, Wilkinson GR. Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther. 1990;48:10-17.
247. Hosseine SJ, Farid F, Ghalighi MR, et al. Interethnic differences in drug protein binding and alpha 1 acid glycoprotein concentration. Ir J Med Sci. 1995;164:26-27.
248. Gilmore DA, Gal J, Gerber JG, et al. Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther. 1992;261:1181-86.
249. Walle UK, Fagan TC, Topmiller MJ, et al. The influence of gender and sex steroid hormones on the plasma binding of propranolol enantiomers. Br J Clin Pharmacol. 1994;37:21-25.
250. Feely J, Grimm T. A comparison of drug protein binding and alpha 1-acid glycoprotein concentration in Chinese and Caucasians. Br J Clin Pharmacol. 1991;31:551-52.